DNA
Ginkgo Bioworks Holdings, Inc.NYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.75
P/S
2.51
EV/EBITDA
-3.14
DCF Value
$-37.91
FCF Yield
-45.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.5%
Operating Margin
-185.3%
Net Margin
-183.8%
ROE
-53.7%
ROA
-29.4%
ROIC
-30.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $33.4M | $-80.8M | $-1.43 |
| FY 2025 | $170.2M | $-312.8M | $-5.64 |
| Q3 2025 | $38.8M | $-80.8M | $-1.45 |
| Q2 2025 | $49.6M | $-60.3M | $-1.10 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NYSE
Beta
1.57
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.